Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets

Vascular Pharmacology

Volumn 76, Issue , 2015, Pages 11-17

  Temperilli, Flavia ^a   Di Franco, Manuela ^a   Massimi, Isabella ^a   Guarino, Maria Luisa ^a   Guzzo, Maria Paola ^a   Valesini, Guido ^a   Frati, Luigi ^b   Pulcinelli, Fabio M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

MRP4; NSAID; Osteoarthritis; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; CELECOXIB; DICLOFENAC; MULTIDRUG RESISTANCE PROTEIN 4; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ABCC4 PROTEIN, HUMAN; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WESTERN BLOTTING; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; MEGAKARYOCYTE; METABOLISM; MIDDLE AGED; THROMBOCYTE ACTIVATION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELECOXIB; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; FEMALE; HUMANS; MEGAKARYOCYTES; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAPROXEN; OSTEOARTHRITIS; PLATELET ACTIVATION; PLATELET AGGREGATION; RNA, MESSENGER;

EID: 84961194034     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.06.016     Document Type: Article

References (26)

1. F.G. Russel, J.B. Koenderink, R. Masereeuw, Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules, Trends Pharmacol. Sci. 29 (2008) 200-207
2. T. Mattiello, R. Guerriero, L.V. Lotti, E. Trifiro, M.P. Felli, A. Barbarulo, et al., Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting, J. Am. Coll. Cardiol. 58 (2011) 752-761
3. I. Massimi, R. Guerriero, L.V. Lotti, V. Lulli, A. Borgognone, F. Romani, et al., Aspirin influences megakaryocytic gene expression leading to upregulation of Multidrug Resistance Protein-4 in human platelets, Br. J. Clin. Pharmacol. 78 (6) (2014) 1343-1353
4. A. Yessoufou, W. Wahli, Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels, Swiss Med. Wkly. 140 (2010) w13071
5. V.R. Narala, R.K. Adapala,M.V. Suresh, T.G. Brock, M. Peters-Golden, R.C. Reddy, Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferatoractivated receptor-alpha agonist, J. Biol. Chem. 285 (2010) 22067-22074
6. V.Y. Ng, Y. Huang, L.M. Reddy, J.R. Falck, E.T. Lin, D.L. Kroetz, Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha, Drug Metab. Dispos. 35 (2007) 1126-1134
7. G.R. Elliott, A.P. Lauwen, I.L. Bonta, Prostaglandin E2 inhibits and indomethacin and aspirin enhance, A23187-stimulated leukotriene B4 synthesis by rat peritonealmacrophages, Br. J. Pharmacol. 96 (1989) 265-270
8. A. Gradilone, I. Silvestri, S. Scarpa, S. Morrone, O. Gandini, F.M. Pulcinelli, et al., Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines, Oncol. Rep. 17 (2007) 823-828
9. S.M. Greenberg, D.S. Rosenthal, T.A. Greeley, R. Tantravahi, R.I. Handin, Characterization of a new megakaryocytic cell line: the Dami cell, Blood 72 (1988) 1968-1977
10. F.M. Pulcinelli, B. Ashby, P.P. Gazzaniga, J.L. Daniel, Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets, FEBS Lett. 364 (1995) 87-90
11. J.E. Freedman, M.G. Larson, K. Tanriverdi, C.J. O'Donnell, K. Morin, A.S. Hakanson, et al., Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study, Circulation 122 (2010) 119-129
12. S.W. Lindemann, C.C. Yost, M.M. Denis, T.M. McIntyre, A.S. Weyrich, G.A. Zimmerman, Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7076-7081
13. M.N. Passarelli, A.E. Coghill, C.M. Hutter, Y. Zheng, K.W. Makar, J.D. Potter, et al., Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a populationbased study of postmenopausal women, Genes Chromosomes Cancer 50 (2011) 875-886
14. G.V.R. Born, The aggregation of blood platelets by adenosine diphosphate and its reversal, Nature 194 (1962) 927-929
15. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, et al., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N. Engl. J. Med. 345 (2001) 1809-1817
16. L.M. Lien, Z.C. Chen, C.L. Chung, T.L. Yen, H.C. Chiu, D.S. Chou, et al., Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo, Eur. J. Pharmacol. 737 (2014) 159-167
17. J.M. Brophy, L.E. Levesque, B. Zhang, The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction, Heart 93 (2007) 189-194
18. E.L. Fosbol, G.H. Gislason, S. Jacobsen, F. Folke,M.L. Hansen, T.K. Schramm, et al., Risk of myocardial infarction and death associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study, Clin. Pharmacol. Ther. 85 (2009) 190-197
19. G.H. Gislason, S. Jacobsen, J.N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, et al., Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction, Circulation 113 (2006) 2906-2913
20. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, K.A. Taubert, et al., Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement fromthe American Heart Association, Circulation 115 (2007) 1634-1642
21. P. McGettigan, D. Henry, Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies, PLoS Med. 8 (2011) e1001098
22. G.A. FitzGerald, C. Patrono, The coxibs, selective inhibitors of cyclooxygenase-2, N. Engl. J. Med. 345 (2001) 433-442
23. G.A. Fitzgerald, Coxibs and cardiovascular disease, N. Engl. J. Med. 351 (2004) 1709-1711
24. A. Borgognone, F.M. Pulcinelli, Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport, Thromb. Haemost. 108 (2012) 955-962
25. C.N. Floyd, T. Goodman, S. Becker, N. Chen, A. Mustafa, E. Schofield, et al., Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirinresistant but not aspirin-sensitive subjects, Br. J. Clin. Pharmacol. 78 (2014) 320-328
26. D. Voora, D. Cyr, J. Lucas, J.T. Chi, J. Dungan, T.A. McCaffrey, et al., Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events, J. Am. Coll. Cardiol. 62 (2013) 1267-1276